Glenmark Pharmaceuticals Europe (Glenmark) has launched a generic version of Seretide Accuhaler in Denmark. This is Glenmark’s first inhaled respiratory product launch in Europe. Glenmark is the first generic company to receive regulatory approval for substitution in Denmark for its generic of Seretide Accuhaler.
Glenmark had entered into a strategic development & licensing agreement with Celon Pharma S.A. (Celon) to develop and market a generic version of GlaxoSmithKline’s Seretide Accuhaler product - Fluticasone/Salmeterol dry powder inhaler in 15 European countries. Fluticasone/Salmeterol dry powder inhaler is a combination product for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Glenmark has already received National Marketing Authorizations for the product in Sweden, Finland, Norway and Iceland. According to IQVIA data, Fluticasone/Salmeterol Dry powder Inhaler (DPI) had sales of $864 million in Europe in the 12 month period ending September 2017.
